Prevalence and determinants of oral human papillomavirus infection in 500 young adults from Italy by Lupato, Valentina et al.
Original Citation:
Prevalence and determinants of oral human papillomavirus infection in 500 young adults from Italy
Public Library of Science
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3218096 since: 2017-02-01T09:42:30Z
10.1371/journal.pone.0170091
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
RESEARCH ARTICLE
Prevalence and Determinants of Oral Human
Papillomavirus Infection in 500 Young Adults
from Italy
Valentina Lupato1,2☯, Dana Holzinger3☯, Daniela Ho¨fler3, Anna Menegaldo1, Paolo Giorgi
Rossi4,5, Annarosa Del Mistro6, Maria Cristina Da Mosto1, Michael Pawlita3‡,
Paolo Boscolo-Rizzo1‡*
1 Department of Neurosciences, Regional Center for Head and Neck Cancer, University of Padua, Treviso,
Italy, 2 Unit of Otolaryngology, Azienda Ospedaliera “S. Maria degli Angeli”, Pordenone, Italy, 3 Division of
Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer
Research Center (DKFZ), Heidelberg, Germany, 4 Interinstitutional Epidemiology Unit, Local Health
Authority, Reggio Emilia, Italy, 5 Arcispedale S. Maria Nuova, IRCCS, Reggio Emilia, Italy, 6 Immunology
and Molecular Oncology Unit, Istituto Oncologico Veneto—IRCCS, Padova, Italy
☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* paolo.boscolorizzo@unipd.it
Abstract
Although the prevalence of human papillomavirus (HPV)-related oropharyngeal squamous
cell carcinoma (OPSCC) is increasing in developed countries and becoming a relevant
health issue, the natural history of oral HPV infection is still unclear. Estimating the infec-
tion’s prevalence in specific populations and identifying risk factors can widen our under-
standing of its natural history and help to delineate appropriate prevention strategies. This
study sought to (i) determine oral HPV prevalence and genotype distribution in a large series
of young Italian adults, (ii) validate an oral rinse sampling/storage protocol, and (iii) pinpoint
factors associated with oral HPV infection. Five hundred students, nurses, and technicians
(19–35 years-old) studying and working at/for the University of Padua were recruited. Each
participant was provided with an oral rinse sampling kit and instructions for use. They were
also asked to complete an anonymous questionnaire concerning their demographic charac-
teristics and behaviors. The questionnaires and oral rinse containers were labeled with the
same identification code number. The oral rinse samples were tested using a bead-based
multiplex BSGP5+/6+-MPG genotyping assay which amplifies the L1 region of 51 mucosal
HPV types. The prevalence of oral HPV infection was 4.0% (95% confidence interval (CI),
2.5%-6.1%); those of 14 high-risk HPV types and of HPV-type 16 (HPV16) infection were
2.2% (95% CI, 1.1%-3.9%) and 1.6% (95% CI, 0.6%-3.1%), respectively. HPV16 was the
most frequent genotype (40.0% of oral HPV infections). No association was found between
oral infection and the co-variables studied (gender, tobacco, alcohol and illegal drug use,
number of sex and oral sex partners, HPV vaccination status, history of HPV and sexually
transmitted infections, abnormal pap smears, recurrent tonsillitis and tonsillectomy). The
oral rinse sampling protocol outlined here proved to be simple, efficient and well tolerated,
and the prevalence rate can be considered reliable and thus useful to guide future research.
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Determinants of oral HPV infection are still unclear and further studies are certainly
warranted.
Introduction
Head and neck cancer affects approximately 750,000 new patients worldwide every year with
the most common type being head and neck squamous cell carcinoma (HNSCC), a frequently
lethal cancer that develops in the epithelial linings of the oral cavity, pharynx, and larynx [1, 2].
Although HNSCC is by far strongly associated with tobacco use and heavy alcohol consump-
tion, in the last two decades, the role of high-risk human papillomaviruses (HPV) is emerged
as an important etiological factor for a subset of HNSCC arising from the oropharynx. The
incidence of HPV-driven oropharyngeal SCC (OPSCC) is dramatically increasing in devel-
oped countries predominantly affecting men, at younger age than tobacco and alcohol related
carcinomas and supposed to be mainly linked to changes in sexual behaviors over the past five
decades [3–8]. Present in 45–90% of cases, high-risk HPVs are now considered the main etio-
logic agents of OPSCC in the United States and in Northern Europe [5, 9]. In Northeast Italy,
the prevalence of HPV-driven OPSCC is conversely lower, at 20% [10].
Oral HPV infection is the presumed precursor of HPV-driven OPSCC. However, the natu-
ral history of oral HPV infection is not yet entirely understood. Estimating its prevalence in
specific populations and identifying its determinants are, therefore, essential steps to devise
appropriate prevention strategies. Studies investigating the prevalence of oral HPV infection
in healthy subjects have, however, uncovered a high variability in the prevalence in different
populations, with values ranging between 0.2% and 20.7% [11–33]. The two studies that have
investigated its prevalence in healthy Italian populations produced quite different results
[26,27]: according to the first [26], which was carried out in 2007 on a series of healthy Sardin-
ians, its prevalence was estimated at 18.4%, while the second, [27], which was carried out in
2012 on a series of healthy Italians living in a Northern region, produced a much lower figure
(1.2%).
Part of a multicenter European project and coordinated by the German Cancer Research
Center based in Heidelberg (Germany), this study aimed to investigate the prevalence of oral
HPV infection in a large Italian population of healthy subjects. The study specifically set out to
(i) determine oral HPV prevalence and genotype distribution in a sample of young adults, (ii)
validate an oral rinse and gargle collection and storage protocol, and (iii) identify factors asso-
ciated with oral HPV infection.
Materials and Methods
Study design and subjects
This cross-sectional study was conducted between July 2014 and January 2015. Five-hundred
students, nurses and technicians studying and working at/for the University of Padua, were
recruited. Inclusion criteria were age 18–35 years and signed informed consent. Exclusion cri-
teria included history of head and neck cancer and ongoing diseases of the upper aerodigestive
tract. Potential participants who were contacted during classes or through student representa-
tives by email messages or telephone calls were informed that investigators would not register
any identifying details and that anonymity would be protected. Subjects who agreed to partici-
pate signed informed consent forms. Each participant was given a questionnaire together with
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an oral rinse sample kit. Both were labeled with the same unique identification number. The
study was approved by the local Clinical Trials Ethics Committee (Ethic vote 54/CE/AULSS9).
Questionnaire
Each participant was asked to answer an anonymous questionnaire (please see Appendix A in
S1 File) investigating variables concerning age, sex, education level, HPV vaccination status
(the number, dates and types of vaccinations), history of recurrent tonsillitis, previous tonsil-
lectomy, use of tobacco, alcohol and/or illegal drugs, number of same- and opposite-sex part-
ners for genital and oral sex, history of former and current infections (cutaneous and genital
HPV, Herpes simplex virus types 1 and 2, Candida albicans, Chlamydia trachomatis, Neisseria
gonorrhoeae, Treponema pallidum, Trichomonas vaginalis, Gardnerella vaginalis, human
immunodeficiency virus). Female participants were asked about the results of their Pap smears
and if they had been treated for cervical lesions.
Oral rinse samples
Each participant received an oral rinse sampling kit and instructions for use. They were di-
rected to rinse and gargle with 10 ml mouth wash solution (Listerine Cool Mint—Johnson &
Johnson1) for 30 seconds. After alternating rinsing and gargling they were asked to expecto-
rate into a sterile container that was sealed and consigned to one of the study coordinators.
The specimens were stored at -20˚C in the Pathology Department of the Treviso Regional
Hospital and later sent to the German Cancer Research Center (DKFZ) in Heidelberg, Ger-
many for HPV analyses.
DNA extraction
Oral rinse samples were thawed at room temperature, vortexed and 500 μL were used for auto-
mated DNA extraction. Extraction was done using the MagNa Pure 96 DNA and Viral NA
Large Volume Kit on the platform of the MagNa Pure 96 instrument in combination with the
‘Pathogen universal 500’ protocol. DNA was eluted in 50 μL elution buffer (Roche, Mannheim,
Germany) and stored at -20˚C until further processing.
BSGP5+/6+-PCR/Multiplex HPV genotyping
The BSGP5+/6+-PCR/MPG assay comprises the BSGP5+/6+-PCR, which homogenously
amplifies a ~150 bp amplicon from the L1 region of 51 mucosal HPV types, sequences of the
β-globin gene and internal controls [34] and the subsequent MPG hybridization assay with
bead-based Luminex xMAP suspension array technology that is able to simultaneously identify
and quantify the 51 HPV types (12 high-risk HPV types: HPV16, -18, -31, -33, -35, -39, -45,
-51, -52, -56, -58, -59; one probably high-risk HPV type: HPV68; 7 possibly high-risk HPV
types: HPV26, -53, -66, -67, -70, -73, and -82; HPV31 low-risk HPV types: HPV6, -7, -11, -13,
-30, -32, -34, -40, -42, -43, -44, -54, -61, -62, -69, -71, -72, -74, -81, -83, -84, -85, -86, -87, -89,
-90, -91, -97, -102, -106, and -114) and the β-globin gene [35]. Briefly, 5 μL DNA were used for
PCR and amplification was performed utilizing the Multiplex PCR Kit (Qiagen, Hilden, Ger-
many) using 0.2–0.5 μM of each BSGP5+ and 5´-biotinylated BSGP6+ primers and 0.15 μM of
each β-globin primer MS3 and 5´-biotinylated MS10. Following PCR amplification, 10 μL of
each reaction mixture was hybridized to bead-coupled probes, as described elsewhere [34].
Bound biotinylated amplimers were quantified using the Luminex 100 analyzer. The median
reporter fluorescence intensity (MFI) of at least 100 beads was computed for each bead set in
the sample.
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Cut-off definition
The cut-off for each sample was defined as 5 + 1.5median net MFI of all 63 probes (specific
for the 51 HPV types plus ß-globin, and internal controls for extraction, hybridization, and
PCR performance). This sample-specific cut-off was subtracted from each net MFI value. Neg-
ative values were set to 0.
Presence of HPV
HPV-type was defined as “positive” if the type-specific MFI value was above the cut-off (> 0
MFI). A sample was defined as “DNA valid” if either an HPV-type or ß-globin was above cut-
off.
Sample size calculation
The size of the population that was required by our study was calculated using the following
formula:
n0 ¼
ua2pð1   pÞ
@2
where n0 is the estimated sample size, π is the expected prevalence of the HPV infection, @ is
the precision of the estimate, α is = 0.05, and uα = 1.96. Based on data from a series of previous
studies [36], we expected an all-type HPV prevalence of 5%. We calculated that a sample size
of 457 subjects was needed in order to obtain a precision of the estimate of all-type HPV preva-
lence not exceeding ±2.5%. As we expected a participation rate of 75%, 600 subjects were
invited to participate.
Statistical analysis
Descriptive statistics were used to summarize the participants’ characteristics (median, range,
and proportion). HPV positive individuals were compared with HPV negatives to identify
characteristics associated with oral HPV infection. The percentage of HPV positive of each
group and the prevalence ratio (i.e. the prevalence of infection in exposed divided by the prev-
alence of infection in the non-exposed) with relative 95% confidence intervals (95% CI) were
calculated. The chi-square test (or Fischer’s exact test when the expected number in any cell
was<5) was used for comparisons between two categorical variables. For all the relevant com-
parisons p-values, calculated according to a two tailed probability distribution, are reported.
The SPSS 17.0 Statistics (SPSS Inc, Chicago, IL) and STATA 13 software packages were used to
compute 95% CI (StataCorp LP, College Station, TX).
Results
Characteristics of the study population
We have no demographic information about the 38 subjects who declined to participate in the
study. The recruitment process was concluded when we had recruited 500 participants who
provided informed consent. The participants were all students, nurses, and technicians (253
females and 247 males) studying and working at/for the University of Padua (Table 1). The
median age of the participants was 23 years (range 19–35). The median age of females was 22
(range 19–35 years) and of males was 23 years (range 19–35 years). All participants were
Caucasian.
None of the males had been vaccinated against HPV, while 43/253 females (17.0%) had
undergone HPV vaccination. Sixteen declared that they had received 3 doses of a quadrivalent
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HPV vaccine (Gardasil1), and four declared they had received 3 doses of a bivalent HPV vac-
cine (Cervarix1); the remaining 23 did not specify the vaccine type or the number of doses
they had received (Table 1).
More male participants (60.4% compared to 34.9% of females) reported having more than
one drink a week and taking illegal drugs (40.8% compared to 20.4%. of the females, Table A
in S1 File).
Males declared that they had more sex partners than women, i.e. 11.1% females and 25.7%
males had>5 lifetime sex partners and 13.2% females and 23.8% males had two or more sex
partners during the last 12 months (Table B in S1 File).
Complications during sample collection
No complications were reported during the sampling process. All of the participants carried
out the oral rinse protocol without any difficulty.
Table 1. Participants’ characteristics by oral HPV status.
Characteristics Total HPV positive Prevalence ratio 95% CI
(N = 500) (N = 20)
Gender Female 253 10(4.0%) 1
Male 247 10(4.0%) 1.02 0.43–2.42
Age (years) 19–24 333 15(4.5%) 1
25–29 98 2(2.0%) 0.45 0.11–1.95
30–35 62 2(3.2%) 0.72 0.17–3.05
Missing data 7 1 -
Education High school 365 16(4.4%) 1
Degree 134 4(3.0%) 0.68 0.23–2.00
Missing data 1 0 -
Smoking Never/former 408 18(4.4%) 1
Current 88 2(2.3%) 0.52 0.12–2.18
Missing data 4 0 -
Alcohol <1drink/week 257 10(3.9%) 1
>1drink/week 237 9(3.8%) 0.98 0.40–2.36
Missing data 6 1 -
Illegal drug use Never 342 13(3.8%) 1
Ever 148 7(4.7%) 1.24 0.51–3.06
Missing data 10 0 -
Cannabis 148 7(4.7%) -
Cocaine 11 0(0.0%) -
Hallucinogenic 5 0(0.0%) -
Opiates 2 0(0.0%) -
History of tonsillectomy No 457 18(3.9%) 1
Yes 37 2(5.4%) 1.37 0.33–5.69
Missing data 6 0 -
History of recurrent tonsillitis No 461 19(4.1%) 1
Yes 33 1(3.0%) 0.74 0.10–5.32
Missing data 6 0
HPV vaccination status Unvaccinated 457 18(3.9%) 1
Vaccinated 43 2(4.7%) 1.18 0.28–4.92
CI confidence interval; HPV human papillomavirus.
doi:10.1371/journal.pone.0170091.t001
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Oral HPV prevalence and HPV types
All oral rinse and gargle samples were positive for β-globin. Twenty of 500 participants tested
positive for oral HPV infection (prevalence 4.0%, 95% CI, 2.46%-6.11%). Out of the 51 HPV
types that were tested, nine were detected in the study population (HPV6, -11, -16, -30, -52,
-53, -56, -81, -90). The high-risk and low-risk HPV infection prevalence were 2.2% (95% CI,
1.10%-3.90%) and 2.0% (95% CI, 0.96%-3.65%), respectively. Nineteen of the HPV positive
samples had single HPV-type; one had a co-infection (HPV16 and HPV81). HPV16 was the
most prevalent HPV-type identified in 8/20 (40%) oral HPV-DNA positive participants (prev-
alence 1.6%; 95% CI, 0.63%-3.13%) (Fig 1).
Characteristics and behaviors associated with oral HPV infection
The median age of oral HPV positive participants was 21 (range 19–33 years), and of HPV
negative 23 years (range 19–35 years) (p = 0.100). The prevalence of oral HPV infection was
4.5% (95% CI, 2.54%-7.32%) in the 19–24 year-old group, 2.0% (95% CI, 0.25%-7.18%) in the
25–29 year-old group, and 3.2% (95% CI, 0.39%- 11.17%) in the 30–34 year-old group.
None of the variables investigated (gender, age, education, illegal drug use, tobacco smok-
ing, alcohol consumption, history of tonsillectomy and of recurrent tonsillitis, number of sex
and oral sex heterosexual and homosexual partners lifetime and over the previous 12 months)
were statistically significantly associated with oral HPV infection (Tables 1, 2, and Table C in
S1 File). A history of previous sexually transmitted infections was not significantly associated
with oral HPV infection (Table D in S1 File).
Fig 1. Number of HPV positive samples. Number of HPV genotypes detected in oral rinse and gargle samples of the 500 participants. One participant had a
co-infection, HPV16 and HPV81. Black bars, high-risk HPV; grey bars, low-risk HPV. HPV human papillomavirus.
doi:10.1371/journal.pone.0170091.g001
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Among the 90 women who declared to have undergone Pap smear testing, two were oral
HPV positive, eleven had abnormal Pap smear results and 6 of them underwent treatment.
One of oral HPV positive women had an abnormal Pap smear results (Table 3).
Table 2. Number of heterosexual sex partners stratified by oral HPV status.
Characteristics Total HPV positive Prevalence ratio 95% CI
(N = 500) (N = 20)
Heterosexual partners/lifetime 0 57 4 7.0%) 1.99 0.56–7.16
1 142 5(3.5%) 1
2–5 188 7(3.7%) 1.06 0.34–3.26
6–10 59 4(6.8%) 1.32 0.36–4.79
11–19 18 0(0.0%)
>19 9 0(0.0%)
Missing data 27 0 -
Heterosexual partners/last 12 months 0 99 6(6.1%) 1.97 0.72–5.40
1 293 9(3.1%) 1
2–5 81 5(6.2%) 1.85 0.64–5.38
6–10 4 0(0.0%)
11–19 2 0(0.0%)
>19 1 0(0.0%)
Missing data 20 0 -
Oral heterosexual partners/lifetime 0 80 4(5.0%) 0.88 0.27–2.83
1 141 8(5.7%) 1
2–5 183 5(2.7%) 0.48 0.16–1.44
6–10 46 3(6.5%) 0.74 0.20–1.72
11–19 14 0(0.0%)
>19 11 0(0.0%)
Missing data 25 0 -
Oral heterosexual partners/last 12 months 0 118 7(5.9%) 1.62 0.63–4.15
1 273 10(3.7%) 1
2–5 76 3(3.9%) 0.96 0.27–3.42
6–10 4 0(0.0%)
11–19 4 0(0.0%)
>19 1 (0.0%)
Missing data 24 0 -
CI confidence interval; HPV human papillomavirus.
doi:10.1371/journal.pone.0170091.t002
Table 3. History of Pap smear testing and oral HPV status.
Pap test Total female HPV positive Prevalence ratio 95% CI
(N = 253) (N = 10)
Never 140 7 (5.0%)
Underwent testing 90 2 (2.2%) 0.44 0.09–2.09
Missing data 23 1 -
Abnormalities 11 1 (9.1%) 6.64a 0.45–98.58
Treatment 6 1 (16.7%) 12.00a 0.65–178.79
CI confidence interval; HPV human papillomavirus.
a Prevalence ratio versus women with normal Pap smear results.
doi:10.1371/journal.pone.0170091.t003
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Two of the vaccinated women were oral HPV positive, i.e. one was HPV16 positive and the
other was HPV6 positive (Table 1). The HPV16 positive woman had received three doses of
Gardasil1 in 2012 and the HPV6 positive woman did not specify the type or number of doses
of vaccine she had received.
Discussion
This is the first study investigating the prevalence of oral HPV infection in a large Italian popu-
lation of young adults. In the light of the dramatic rise in HPV-associated OPSCC, the study
set out to (i) determine oral HPV prevalence and genotype distribution, (ii) validate a repro-
ducible oral rinse sampling and storage protocol, and (iii) identify factors associated with oral
HPV infection, in a series of young adults from Italy.
As oral cytobrush or swab samples were found to provide insufficient DNA quality com-
pared to oral rinse and gargle [37–39], we adopted this second methodology for the present
study. Our oral rinse sampling protocol can be considered safe and well-tolerated as no com-
plications/problems were reported, and, in fact, all of the participants completed the rinsing/
gargling sequence in 30 seconds. All samples were positive for the ß-globin gene confirming
that the processing and storage procedures were indeed efficacious. This sampling procedure
may also be applied to monitor patients treated for HPV-driven OPSCC for the early detection
of local relapses [40] and to identify a high-risk HPV infection in patients with an occult SCC
metastatic to neck lymph nodes, thus guiding the search of the hidden primary in the orophar-
ynx [41].
A bead-based multiplex genotyping of 51 mucosal HPV-types, a powerful tool for genotyp-
ing single and multiple HPV infections that is suitable for large-scale epidemiological studies,
was used here [35]. The overall oral HPV infection prevalence found in our population sample
was 4.0% with HPV16 being the most frequent genotype found (1.2%). The prevalence of oral
HPV infection was recently calculated in a systematic review of the literature including around
4,600 healthy individuals from different countries and continents [36]. Interestingly, the over-
all prevalence was comparable to our study: 4.5% and 1.3% for all types of HPV infection and
HPV16 infection, respectively. The only two studies [26,27] that have investigated the preva-
lence of oral HPV infection in samples of healthy Italian population from quite different
cohorts produced ambiguous data and high prevalence variability (1.2% and 18.4%, respec-
tively). A high inconsistency in the overall prevalence of oral HPV infection is in common
with other studies, with values ranging between 0.2% and 20.7% [11–33]. This may partially be
related to the different inclusion criteria, clinical setting, sampling methods and detection
assays. However, it could also reflect real differences in HPV exposure in different geographi-
cal and social contexts as well as biological and genetic differences in the population investi-
gated. Supporting this hypothesis, two large studies both conducted in >5,000 individuals
from United States [17] and China [19], reported an overall prevalence of oral HPV infection
of 6.8% and 0.6%, respectively. Of interest, these data reflect the rates of HPV-positive OPSCC
in these different areas [42,43]. The percentage of HPV-driven OPSCC has been reported to be
low in Northeast Italy [10]. A similar prevalence of oral HPV16 infection in the young popula-
tion of our study and in the US population studied [17] may reflect changing sexual habits in
the Italian population, and it is possible that we will see an increase in HPV-driven OPSCC in
the years to come.
We did not find statistically significant associations between oral HPV infection and age,
gender, tobacco smoking, abuse of alcohol or illegal drugs, number of sex and oral sex part-
ners, history of infections and of abnormal pap smears, previous tonsillectomy or recurrent
tonsillitis and vaccination against HPV. It cannot, however, be excluded that even if the
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population studied was rather large, the overall prevalence of oral HPV infection was too low
to allow us to investigate the determinants of the infection. The finding of a higher risk of
HPV infection in subjects without any partners in their lifetime was quite unexpected, but
could be compatible with a purely random data fluctuation. Furthermore, given our sample
size, we had 50% power to detect a significant difference in prevalence, just as that observed by
Chaturvedi et al. between the exposed and unexposed subjects [4]. In an US population (aged
14–69 years) the prevalence of oral HPV infection was 6.9% with peak prevalence of 7.3%
among participants aged 30–34 years and 11.4% among participants aged 60–64 years [17]. An
increasing prevalence with age was also found in an Australian study [11] (aged 18–35 years)
which reported that the overall prevalence of 2.3% had a peak of 4.8% in the 25–35 age group.
The incongruous pattern that was noted (but without statistically significant differences) in
our population in which the prevalence was higher in the 19–24 year-old group (4.8%) than in
the 25–29 (2.0%) and 30–35 year-old groups (3.2%) could be explained by different behavior
trends in younger population groups living in the same geographic areas.
Several studies [11,44] have found a higher prevalence in men; this finding could be partly
related to the significantly higher number of lifetime sex partners in men than in women
[17,44]. It is important to remember, however, that men traditionally tend to over-report and
women to under-report sexual partnerships [44]. Although the men participating in our study
did indeed report a higher number of lifetime sex partners (p<0.001), of sex partners during
last 12 months (p = 0.011), and of lifetime oral sex partners (p<0.001), just as in other studies
[19,45], no gender difference was observed in the prevalence of oral HPV infection in our
study population.
A recent Danish study [46] reported that tonsillectomy significantly reduced the risk of
tonsillar carcinoma diagnosis [incidence rate ratio (RR), 0.40; 95% CI, 0.22–0.70]. In view of
the tropism of HPV to tonsillar tissue [47], it would be interesting to study the prevalence of
oral HPV infection in a large population of individuals who had undergone tonsillectomy.
Although we did not find that tonsillectomy had a significantly protective effect on oral HPV
infection, it was indeed detected in two individuals who underwent the operation. It is not in
any case possible to establish the site of infection using the methodology outlined here. The
base of the tongue, rich in lymphoepithelial tissue which is the preferential substratum for
HPV infection, could be the site of infection in those individuals with previous tonsillectomy.
Some 17% of the female participants enrolled in our study had been vaccinated against HPV.
The only studies [39,48,49] investigating the effect of HPV vaccination on oral HPV infection
in females reported a lower prevalence of oral HPV infection in the vaccinated group. Here in
this region of Italy, the most utilized HPV vaccine is the quadrivalent vaccine (Gardasil1)
that provides protection against HPV types 6, 11, 16 and 18. Unexpectedly, two vaccinated
individuals participating in our study resulted positive to oral HPV infection: one was HPV16
positive and the other was HPV6 positive. There were no statistically significant differences in
oral HPV infection prevalence in the vaccinated and unvaccinated groups. It is in any case pos-
sible that the oral HPV infection had already been acquired before they were vaccinated, or
that it was a very recent infection, as the immune system needs some months to be activated
and clear the infection.
Since there is not yet any validated method to screen for HPV-driven OPSCC [49], HPV
vaccination seems the best path to prevent oral HPV infection and to halt the rise in HPV-
driven OPSCC incidence. Just as in other European countries, recent studies and findings
have led to new cost-effectiveness calculations that favor expanding the HPV vaccination pro-
gram to boys [50] in view of new updated models [51]. The Veneto and other Italian regions
[52] have, indeed, switched to and are implementing universal vaccination programs.
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Conclusions
This is the first large study conducted on the prevalence of oral HPV infection in Italy. The
reproducible oral rinse sampling/storage protocol outlined here was efficient and well tolerated.
The overall prevalence of oral HPV infection in a population of young Italians was 4.0% with
HPV16 being by far the most frequently detected genotype. Risk factors for oral HPV infection
are nevertheless still unclear and further studies are certainly warranted. The data presented here
can moreover be used to guide further research and for systematic reviews and meta-analysis.
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